Brad Hornberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brad Hornberger has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Solomon Lukasz Woldu
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
2 shared publications - Yair Lotan
Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Aditya Bagrodia
Department of Urology, UC San Diego School of Medicine, La Jolla, CA; Department of Urology, UTSW School of Medicine, Dallas, TX
1 shared publication Claus G. Roehrborn
Department of Urology, UT Southwestern Medical Center, Dallas, TX
1 shared publication- Claus G. Roehrborn
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas
1 shared publication - Daniel N. Costa
Division of Diagnostic Imaging The University of Texas MD Anderson Cancer Center Houston Texas USA
1 shared publication
Latest Publications
- 1 January 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (1) , 57-62
Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy
- 1 January 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (1) , 57-62
Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy
- Open Access
- 18 March 2017
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 5 (2) , 124-131
Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures
A number of strategies have been attempted to minimize the risk of infection following transrectal prostate procedures. We report our prospective efforts at augmenting our prophylaxis strategy over time. Since 2010 we have prospectively monitored infections after transrectal prostate procedures and changed our prophylaxis regimen twice in an effort to respond to increases in infectious complications. In 2011 we added a single dose of intramuscular aminoglycoside to our prophylaxis regimen of fluoroquinolones or trimethoprim-sulfamethoxazole. In 2015 we began performing formalin needle tip disinfection before each biopsy and screening high risk patients for antibiotic resistance using rectal swab cultures (targeted prophylaxis). We report our rates of infections and antibiotic resistance patterns during this period. From 2010 to 2016 we performed 2,398 transrectal prostate procedures. Overall there were 41 cases (1.7%) of infection related hospitalization. However, the rate differed significantly during the course of the study period. The infection related hospitalization rate declined from 3.8% to 1.1% in the first 3 years following the addition of intramuscular aminoglycoside (2011 to 2013), a decrease of 69%. In 2014 our infection rate increased to 2.6%, prompting the initiation of protocol 3, wherein the addition of target prophylaxis and formalin needle tip disinfection identified a 29.8% fluoroquinolone resistance rate and resulted in another decline in our infection rate to 1.2% (a decrease of 53%). While the initial addition of intramuscular aminoglycoside appeared to be effective in decreasing post-procedure infections, further augmentation of our prophylaxis regimen through rectal swab screening of high risk patients and formalin needle tip disinfection led to an additional decline in rates of infection related hospitalizations.
- 18 March 2017
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 5 (2) , 124-131
Open AccessProspective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures
A number of strategies have been attempted to minimize the risk of infection following transrectal prostate procedures. We report our prospective efforts at augmenting our prophylaxis strategy over time. Since 2010 we have prospectively monitored infections after transrectal prostate procedures and changed our prophylaxis regimen twice in an effort to respond to increases in infectious complications. In 2011 we added a single dose of intramuscular aminoglycoside to our prophylaxis regimen of fluoroquinolones or trimethoprim-sulfamethoxazole. In 2015 we began performing formalin needle tip disinfection before each biopsy and screening high risk patients for antibiotic resistance using rectal swab cultures (targeted prophylaxis). We report our rates of infections and antibiotic resistance patterns during this period. From 2010 to 2016 we performed 2,398 transrectal prostate procedures. Overall there were 41 cases (1.7%) of infection related hospitalization. However, the rate differed significantly during the course of the study period. The infection related hospitalization rate declined from 3.8% to 1.1% in the first 3 years following the addition of intramuscular aminoglycoside (2011 to 2013), a decrease of 69%. In 2014 our infection rate increased to 2.6%, prompting the initiation of protocol 3, wherein the addition of target prophylaxis and formalin needle tip disinfection identified a 29.8% fluoroquinolone resistance rate and resulted in another decline in our infection rate to 1.2% (a decrease of 53%). While the initial addition of intramuscular aminoglycoside appeared to be effective in decreasing post-procedure infections, further augmentation of our prophylaxis regimen through rectal swab screening of high risk patients and formalin needle tip disinfection led to an additional decline in rates of infection related hospitalizations.